- Home
- NLSP vs ALBT Comparison
NLSP vs ALBT Comparison
Compare NLSP & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- ALBT
- Stock Information
- Founded
- NLSP 2015
- ALBT 2014
- Country
- NLSP Switzerland
- ALBT United States
- Employees
- NLSP N/A
- ALBT N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NLSP Health Care
- ALBT Health Care
- Exchange
- NLSP Nasdaq
- ALBT Nasdaq
- Market Cap
- NLSP 12.4M
- ALBT 5.7M
- IPO Year
- NLSP 2021
- ALBT N/A
- Fundamental
- Price
- NLSP $2.50
- ALBT $2.68
- Analyst Decision
- NLSP
- ALBT
- Analyst Count
- NLSP 0
- ALBT 0
- Target Price
- NLSP N/A
- ALBT N/A
- AVG Volume (30 Days)
- NLSP 411.8K
- ALBT 97.9K
- Earning Date
- NLSP 07-15-2025
- ALBT 08-18-2025
- Dividend Yield
- NLSP N/A
- ALBT N/A
- EPS Growth
- NLSP N/A
- ALBT N/A
- EPS
- NLSP N/A
- ALBT N/A
- Revenue
- NLSP N/A
- ALBT $807,235.00
- Revenue This Year
- NLSP N/A
- ALBT N/A
- Revenue Next Year
- NLSP N/A
- ALBT N/A
- P/E Ratio
- NLSP N/A
- ALBT N/A
- Revenue Growth
- NLSP N/A
- ALBT N/A
- 52 Week Low
- NLSP $1.30
- ALBT $2.11
- 52 Week High
- NLSP $15.59
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- NLSP 52.64
- ALBT 39.39
- Support Level
- NLSP $2.16
- ALBT $2.60
- Resistance Level
- NLSP $3.08
- ALBT $3.88
- Average True Range (ATR)
- NLSP 0.24
- ALBT 0.28
- MACD
- NLSP -0.00
- ALBT 0.00
- Stochastic Oscillator
- NLSP 30.21
- ALBT 14.84
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.